Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen

This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.

Insider divested 2% of direct holdings via pre-planned Rule 10b5-1 trading arrangement, following a 90% stock surge over the past year.

This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.

Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.

Mineralys (MLYS) Q1 2026 Earnings Transcript

This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Mineralys (MLYS) Q4 2025 Earnings Call Transcript

When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Mineralys Therapeutics beat Q3 2025 EPS estimates. The biotech firm is advancing its lead drug, lorundrostat, toward a planned FDA submission.

Here's what needs to happen for these high flyers to continue soaring.

A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one thing is certain; after a year of tech-led mega caps setting new highs, investors have clearly shown an increased appetite for risk in the form of smaller, lesser known names.

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.